Compugen Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Compugen ha aumentado sus beneficios a una tasa media anual de 0.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 15.5%. Los ingresos han ido creciendo a una tasa media de 54.3% al año.
Información clave
0.4%
Tasa de crecimiento de los beneficios
8.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | 54.3% |
Rentabilidad financiera | -28.0% |
Margen neto | -46.3% |
Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04Desglose de ingresos y gastos
Cómo gana y gasta dinero Compugen. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Mar 24 | 36 | -17 | 10 | 33 |
31 Dec 23 | 33 | -19 | 10 | 34 |
30 Sep 23 | 8 | -32 | 10 | 31 |
30 Jun 23 | 8 | -33 | 11 | 32 |
31 Mar 23 | 8 | -33 | 11 | 31 |
31 Dec 22 | 8 | -34 | 11 | 31 |
30 Sep 22 | 0 | -39 | 11 | 29 |
30 Jun 22 | 6 | -34 | 12 | 29 |
31 Mar 22 | 6 | -34 | 12 | 29 |
31 Dec 21 | 6 | -34 | 12 | 29 |
30 Sep 21 | 8 | -34 | 12 | 31 |
30 Jun 21 | 2 | -36 | 11 | 28 |
31 Mar 21 | 2 | -32 | 11 | 25 |
31 Dec 20 | 2 | -30 | 11 | 23 |
30 Sep 20 | 0 | -28 | 10 | 19 |
30 Jun 20 | 0 | -26 | 10 | 18 |
31 Mar 20 | 0 | -26 | 10 | 18 |
31 Dec 19 | 0 | -27 | 9 | 20 |
30 Sep 19 | 0 | -30 | 9 | 23 |
30 Jun 19 | 8 | -27 | 9 | 26 |
31 Mar 19 | 8 | -31 | 9 | 30 |
31 Dec 18 | 18 | -23 | 10 | 30 |
30 Sep 18 | 18 | -23 | 10 | 30 |
30 Jun 18 | 10 | -29 | 9 | 30 |
31 Mar 18 | 10 | -28 | 9 | 29 |
31 Dec 17 | 0 | -37 | 9 | 29 |
30 Sep 17 | 0 | -36 | 9 | 28 |
30 Jun 17 | 0 | -34 | 9 | 26 |
31 Mar 17 | 1 | -32 | 8 | 25 |
31 Dec 16 | 1 | -32 | 9 | 25 |
30 Sep 16 | 9 | -23 | 8 | 24 |
30 Jun 16 | 9 | -22 | 8 | 23 |
31 Mar 16 | 9 | -23 | 8 | 23 |
31 Dec 15 | 9 | -20 | 7 | 21 |
30 Sep 15 | 8 | -21 | 7 | 20 |
30 Jun 15 | 9 | -20 | 7 | 19 |
31 Mar 15 | 11 | -15 | 7 | 17 |
31 Dec 14 | 12 | -11 | 6 | 15 |
30 Sep 14 | 8 | -13 | 6 | 13 |
30 Jun 14 | 7 | -12 | 6 | 12 |
31 Mar 14 | 6 | -13 | 6 | 13 |
31 Dec 13 | 4 | -14 | 6 | 12 |
30 Sep 13 | 2 | -17 | 5 | 12 |
Ingresos de calidad: CGEN actualmente no es rentable.
Margen de beneficios creciente: CGEN actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CGEN no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 0.4% por año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CGEN en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: CGEN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).
Rentabilidad financiera
Alta ROE: CGEN tiene una rentabilidad financiera negativa (-27.95%), ya que actualmente no es rentable.